Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Analysts

Posted by Geri Gentry on Jun 11th, 2026

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) has been given an average rating of “Buy” by the seventeen research firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, twelve have issued a buy rating and four have given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $56.00.

Several brokerages have recently weighed in on SRRK. JPMorgan Chase & Co. raised their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research note on Monday, March 16th. Citigroup raised their price target on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Wedbush raised their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 1st. Piper Sandler raised their price target on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research note on Tuesday, April 21st.

Check Out Our Latest Stock Analysis on SRRK

Insider Buying and Selling at Scholar Rock

In related news, CEO David Hallal sold 30,615 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $1,517,585.55. Following the completion of the transaction, the chief executive officer directly owned 1,639,034 shares of the company’s stock, valued at approximately $81,246,915.38. This trade represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055 shares of the company’s stock, valued at $30,736,126.35. This represents a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 63,491 shares of company stock valued at $3,147,249 over the last quarter. Insiders own 13.30% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the company. IFP Advisors Inc grew its stake in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Scholar Rock in the fourth quarter valued at $30,000. Summit Securities Group LLC bought a new position in shares of Scholar Rock in the fourth quarter valued at $31,000. EverSource Wealth Advisors LLC grew its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after buying an additional 525 shares in the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Scholar Rock in the fourth quarter valued at $44,000. 91.08% of the stock is owned by institutional investors.

Scholar Rock Price Performance

Shares of SRRK opened at $44.09 on Friday. The stock has a market capitalization of $5.28 billion, a P/E ratio of -12.28 and a beta of 0.69. Scholar Rock has a twelve month low of $27.07 and a twelve month high of $52.19. The company has a 50 day moving average of $48.07 and a 200-day moving average of $45.80. The company has a quick ratio of 8.64, a current ratio of 8.64 and a debt-to-equity ratio of 0.71.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period in the prior year, the company earned ($0.67) EPS. As a group, equities research analysts forecast that Scholar Rock will post -3.23 EPS for the current fiscal year.

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).